Cardiology

ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.

ACC. 24: A structured, systematic approach to lipid-lowering therapy in secondary prevention is needed to ensure targets are met and met swiftly, said researchers.

Your daily dose of the clinical news you may have missed.

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

Your daily dose of the clinical news you may have missed.

Migraine was the most important nontraditional risk factor linked to stroke in adults aged 18 to 34 years and should be considered in evaluation for an event.

Your daily dose of the clinical news you may have missed.

ACC.24: Data showed that individuals who used e-cigarettes were approximately 19% more likely to develop heart failure compared with those who had never vaped.

ACC.2024: Two abstracts presented during the ACC Scientific Sessions indicate cardiologists are very hesitant to prescribe medical therapy for obesity.

Your daily dose of the clinical news you may have missed.

ACC.24: Loss of estrogen's cardioprotective effect could account for the 2-fold greater increase in CAC score seen among postmenopausal women compared with men.

ACC.24: Data showed that participants with ADHD who were prescribed stimulants were 17% more likely to develop cardiomyopathy at 1 year.

Your daily dose of the clinical news you may have missed.

ACC.24: Icosapent ethyl was associated with reduced rate of MACE at all baseline levels of Lp(a) in participants with elevated TG and at high risk for CVD.

Your daily dose of the clinical news you may have missed.

Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.

Your daily dose of the clinical news you may have missed.

ACC.24: Data from an analysis of the CLEAR Outcomes trial showed bempedoic acid was well-tolerated and reduced CV events in Hispanic/Latinx and non-Hispanic/Latinx participants.

CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.

The novel SGLT-2/SGLT-1 inhibitor reduced risk of stroke, MI, and demonstrates significant antiplatelet activity in post-hoc analyses of SCORED phase 3 trial.

ACC.24: Findings showed a disproportionate distribution of CAC screening that favors White, educated, affluent, English-speaking individuals.

ACC.2024: In a cohort of people at high risk of ASCVD, three-quarters achieved target LDL-C levels at 6 months and 12 months while using a remote algorithm-directed program.

Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.

For the first time, 2 drugs recommended as first line treatment for PAH are combined in a single oral once-daily therapy, which could reduced burden of care.

Bempedoic acid is now the only non-statin therapy indicated for primary CVD prevention, with potential to expand treatment access to millions, said Esperion Therapeutics.

CMS says Medicare Part D plans will cover semaglutide for individuals with overweight/obesity who have preexisting CVD, a first after 40 years of legal prohibition.

New research highlights another benefit of COVID-19 vaccination, reported researchers.

Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.

Your daily dose of the clinical news you may have missed.